Teva Operating Income from 2010 to 2025

TEVA Stock

USD 17.84 0.70 3.78%

Teva Pharma's Operating Income is decreasing over the years with very volatile fluctuation. Overall, Operating Income is projected to go to about -287.9 M this year. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Teva Pharma Industries generates from its operations. View All Fundamentals

Operating Income

First Reported

1985-09-30

Previous Quarter

-51 M

Current Value

-29 M

Quarterly Volatility

1.3 B

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Teva Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Teva Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 B, Interest Expense of 1.2 B or Total Revenue of 9.7 B, as well as many indicators such as Price To Sales Ratio of 0.82, Dividend Yield of 0.0041 or PTB Ratio of 1.72. Teva financial statements analysis is a perfect complement when working with Teva Pharma Valuation or Volatility modules.

Check out the analysis of Teva Pharma Correlation against competitors.

Latest Teva Pharma's Operating Income Growth Pattern

Below is the plot of the Operating Income of Teva Pharma Industries over the last few years. Operating Income is the amount of profit realized from Teva Pharma Industries operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Teva Pharma Industries is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Teva Pharma's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Teva Pharma's overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Teva Operating Income Regression Statistics

	Arithmetic Mean	562,378,125
	Geometric Mean	1,433,183,770
	Coefficient Of Variation	903.89
	Mean Deviation	2,830,152,344
	Median	2,205,000,000
	Standard Deviation	5,083,303,222
	Sample Variance	25839971.6T
	Range	21.4B
	R-Value	(0.06)
	Mean Square Error	27569653.9T
	R-Squared	0
	Significance	0.81
	Slope	(69,120,956)
	Total Sum of Squares	387599574.7T

Teva Operating Income History

	2025	-287.9 M
	2024	-303 M
	2023	433 M
	2021	3.2 B
	2020	3.1 B
	2019	2.8 B
	2018	-1.6 B

Other Fundumenentals of Teva Pharma Industries

Non Operating Income Net Other

Teva Pharma Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Short Term Investments	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Good Will	Long Term Investments	Short Long Term Debt	Net Tangible Assets	Deferred Long Term Liab	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.69	0.7	0.25	0.92	0.78	0.84	0.7	0.91	0.13	-0.13	-0.68	0.77	-0.68	0.87	0.31	0.95	0.11	-0.33	-0.61	0.72	0.47	0.14	0.22	-0.14	-0.2
Total Stockholder Equity	0.69		0.07	0.83	0.8	0.23	0.76	0.48	0.57	0.62	-0.63	-0.55	0.11	-0.32	0.57	-0.29	0.63	0.53	0.09	0.03	0.57	-0.2	-0.52	0.63	-0.63	-0.37
Net Debt	0.7	0.07		-0.39	0.54	0.95	0.33	0.54	0.79	-0.48	0.39	-0.4	0.96	-0.58	0.58	0.66	0.8	-0.44	-0.45	-0.94	0.56	0.9	0.64	-0.2	0.34	0.1
Retained Earnings	0.25	0.83	-0.39		0.44	-0.31	0.37	0.2	0.19	0.65	-0.89	-0.12	-0.37	0.2	0.09	-0.59	0.17	0.52	0.5	0.45	0.34	-0.63	-0.88	0.82	-0.88	-0.48
Net Receivables	0.92	0.8	0.54	0.44		0.63	0.87	0.78	0.85	0.27	-0.3	-0.74	0.57	-0.57	0.85	0.28	0.83	0.13	-0.12	-0.38	0.58	0.21	-0.11	0.43	-0.32	-0.32
Total Liab	0.78	0.23	0.95	-0.31	0.63		0.52	0.55	0.78	-0.27	0.38	-0.61	0.92	-0.73	0.73	0.58	0.86	-0.25	-0.57	-0.88	0.55	0.87	0.63	-0.26	0.33	0.21
Total Current Assets	0.84	0.76	0.33	0.37	0.87	0.52		0.64	0.6	0.52	-0.17	-0.86	0.44	-0.71	0.92	0.15	0.69	0.35	-0.27	-0.19	0.36	0.1	-0.03	0.18	-0.17	-0.14
Short Term Debt	0.7	0.48	0.54	0.2	0.78	0.55	0.64		0.71	-0.09	-0.2	-0.59	0.5	-0.28	0.64	0.3	0.61	-0.13	0.1	-0.34	0.39	0.2	-0.02	0.25	-0.23	-0.21
Intangible Assets	0.91	0.57	0.79	0.19	0.85	0.78	0.6	0.71		-0.15	-0.18	-0.43	0.8	-0.46	0.65	0.41	0.92	-0.01	-0.21	-0.74	0.85	0.56	0.12	0.35	-0.22	-0.27
Accounts Payable	0.13	0.62	-0.48	0.65	0.27	-0.27	0.52	-0.09	-0.15		-0.45	-0.41	-0.39	-0.27	0.32	-0.43	0.0	0.62	0.06	0.54	-0.08	-0.57	-0.54	0.34	-0.45	-0.15
Short Term Investments	-0.13	-0.63	0.39	-0.89	-0.3	0.38	-0.17	-0.2	-0.18	-0.45		-0.14	0.38	-0.39	0.08	0.49	-0.04	-0.43	-0.61	-0.38	-0.4	0.6	0.91	-0.85	0.95	0.55
Common Stock	-0.68	-0.55	-0.4	-0.12	-0.74	-0.61	-0.86	-0.59	-0.43	-0.41	-0.14		-0.41	0.78	-0.92	-0.21	-0.6	-0.06	0.34	0.18	-0.09	-0.2	-0.19	0.12	-0.12	-0.12
Long Term Debt	0.77	0.11	0.96	-0.37	0.57	0.92	0.44	0.5	0.8	-0.39	0.38	-0.41		-0.66	0.65	0.67	0.82	-0.32	-0.54	-0.94	0.58	0.88	0.66	-0.2	0.35	0.04
Treasury Stock	-0.68	-0.32	-0.58	0.2	-0.57	-0.73	-0.71	-0.28	-0.46	-0.27	-0.39	0.78	-0.66		-0.85	-0.41	-0.65	-0.08	0.75	0.52	-0.22	-0.53	-0.49	0.29	-0.38	-0.07
Property Plant Equipment	0.87	0.57	0.58	0.09	0.85	0.73	0.92	0.64	0.65	0.32	0.08	-0.92	0.65	-0.85		0.37	0.77	0.05	-0.43	-0.43	0.35	0.38	0.26	-0.04	0.06	0.02
Current Deferred Revenue	0.31	-0.29	0.66	-0.59	0.28	0.58	0.15	0.3	0.41	-0.43	0.49	-0.21	0.67	-0.41	0.37		0.28	-0.38	-0.43	-0.64	0.05	0.62	0.61	-0.2	0.43	0.08
Good Will	0.95	0.63	0.8	0.17	0.83	0.86	0.69	0.61	0.92	0.0	-0.04	-0.6	0.82	-0.65	0.77	0.28		0.0	-0.37	-0.73	0.8	0.62	0.24	0.15	-0.07	-0.1
Long Term Investments	0.11	0.53	-0.44	0.52	0.13	-0.25	0.35	-0.13	-0.01	0.62	-0.43	-0.06	-0.32	-0.08	0.05	-0.38	0.0		-0.07	0.34	0.15	-0.4	-0.46	0.35	-0.41	-0.21
Short Long Term Debt	-0.33	0.09	-0.45	0.5	-0.12	-0.57	-0.27	0.1	-0.21	0.06	-0.61	0.34	-0.54	0.75	-0.43	-0.43	-0.37	-0.07		0.56	-0.13	-0.65	-0.69	0.52	-0.59	-0.3
Net Tangible Assets	-0.61	0.03	-0.94	0.45	-0.38	-0.88	-0.19	-0.34	-0.74	0.54	-0.38	0.18	-0.94	0.52	-0.43	-0.64	-0.73	0.34	0.56		-0.63	-0.95	-0.66	0.22	-0.34	-0.07
Deferred Long Term Liab	0.72	0.57	0.56	0.34	0.58	0.55	0.36	0.39	0.85	-0.08	-0.4	-0.09	0.58	-0.22	0.35	0.05	0.8	0.15	-0.13	-0.63		0.45	-0.07	0.41	-0.41	-0.27
Long Term Debt Total	0.47	-0.2	0.9	-0.63	0.21	0.87	0.1	0.2	0.56	-0.57	0.6	-0.2	0.88	-0.53	0.38	0.62	0.62	-0.4	-0.65	-0.95	0.45		0.84	-0.48	0.55	0.35
Capital Surpluse	0.14	-0.52	0.64	-0.88	-0.11	0.63	-0.03	-0.02	0.12	-0.54	0.91	-0.19	0.66	-0.49	0.26	0.61	0.24	-0.46	-0.69	-0.66	-0.07	0.84		-0.82	0.88	0.58
Net Invested Capital	0.22	0.63	-0.2	0.82	0.43	-0.26	0.18	0.25	0.35	0.34	-0.85	0.12	-0.2	0.29	-0.04	-0.2	0.15	0.35	0.52	0.22	0.41	-0.48	-0.82		-0.87	-0.72
Net Working Capital	-0.14	-0.63	0.34	-0.88	-0.32	0.33	-0.17	-0.23	-0.22	-0.45	0.95	-0.12	0.35	-0.38	0.06	0.43	-0.07	-0.41	-0.59	-0.34	-0.41	0.55	0.88	-0.87		0.48
Capital Stock	-0.2	-0.37	0.1	-0.48	-0.32	0.21	-0.14	-0.21	-0.27	-0.15	0.55	-0.12	0.04	-0.07	0.02	0.08	-0.1	-0.21	-0.3	-0.07	-0.27	0.35	0.58	-0.72	0.48

Click cells to compare fundamentals

About Teva Pharma Financial Statements

Teva Pharma stakeholders use historical fundamental indicators, such as Teva Pharma's Operating Income, to determine how well the company is positioned to perform in the future. Although Teva Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Teva Pharma's assets and liabilities are reflected in the revenues and expenses on Teva Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Teva Pharma Industries. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	-303 M	-287.9 M
Non Operating Income Net Other	-1.2 B	-1.3 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:

How To Invest In Teva

Details

Is Teva Stock a good investment?

Details

What is Teva Pharma's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Teva Pharma Correlation against competitors.

You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.4

Earnings Share

(1.45)

Revenue Per Share

14.879

Quarterly Revenue Growth

0.125

Return On Assets

0.0556

The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Teva Operating Income from 2010 to 2025

Latest Teva Pharma's Operating Income Growth Pattern

Teva Operating Income Regression Statistics

Teva Operating Income History

Other Fundumenentals of Teva Pharma Industries

Teva Pharma Operating Income component correlations

About Teva Pharma Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY